VivoSeq
Nephrology

Membranous Nephropathy

55

Pipeline Programs↗

25

Active Trials↗

32

Companies Involved↗

Membranous Nephropathy is a moderately active landscape with 55 programs across 32 companies. The most active players are Excyte Biopharma Ltd, AstraZeneca, Gilead. 8 therapies are approved with 18 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

27/100

Mech. Concentration

12/100

Completion Rate

83/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Excyte Biopharma Ltd

1 program

Phase 1AstraZeneca logo

AstraZeneca

3 programs

Phase 2Gilead logo

Gilead

2 programs

Phase 2T

Tenet Medicines

2 programs

Phase 2B

Beijing Mabworks Biotech Co., Ltd.

1 program

Phase 2H

HI-Bio, A Biogen Company

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

65 of 74 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody79%Protein / enzyme23%

Small molecule leads; the ring shows all 74 classified programs, each share of the total. Modality classified for 99% of 76 pipeline programs.

Analysis

Trial Status

73

clinical trials

Completed29 · 40%
Recruiting17 · 23%
Unknown status13 · 18%
Not yet recruiting5 · 7%
Withdrawn3 · 4%
Active, not recruiting3 · 4%
Other3 · 4%

Clinical Trials

Trial Activity

73 trials

OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)
Recruiting·HHuashan Hospital·Phase 3·NCT06781944·144 enrolled
Rivaroxaban in Idiopathic Membranous Nephropathy
Recruiting·—·Phase 4·NCT07404436·134 enrolled
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
Recruiting·CClimb Bio, Inc.·Phase 2·NCT07096843·45 enrolled
Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy
Recruiting·SSt. Petersburg State Pavlov Medical University·N/A·NCT05679336·40 enrolled
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome
Recruiting·—·Phase 3·NCT05914155·88 enrolled
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT07157787·30 enrolled
Study of YK012 in Primary Membranous Nephropathy
Recruiting·EExcyte Biopharma Ltd·Phase 1·NCT06982729·72 enrolled
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Recruiting·Biogen logoBiogen·Phase 3·NCT06962800·180 enrolled
Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy
Recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT05514015·78 enrolled
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
Recruiting·—·Phase 4·NCT05839314·480 enrolled
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 2/3·NCT06470191·216 enrolled
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study
Recruiting·RRadboud University Medical Center·Phase 2/3·NCT07163611·20 enrolled
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 1·NCT05668403·52 enrolled
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd logoGuangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT07289763·75 enrolled
Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03949855·58 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)